Experience

IO Biotech

• Denmark
• Biotechnology Research
• 1 - 100 Employee

• Chief Financial Officer

  • 2021 - 2022

  Company successfully taken public on Nasdaq (IOBT). Peak Mrk Cap while there >$400M. Raised ~$200M. Clinical-stage biotech: immuno-oncology. Helped launch onto Nasdaq, navigate public markets, scale team, and execute strategy. Responsibilities: Financial Operations, Transactions, IR and Corp. Comms. * Led $115M IPO & Nasdaq listing (Morgan Stanley, Cowen, Jefferies). * Raised $84M private / crossover round. * Closed 2 Merck collaborations providing pembrolizumab for Ph 3 and Ph… Show more Company successfully taken public on Nasdaq (IOBT). Peak Mrk Cap while there >$400M. Raised ~$200M. Clinical-stage biotech: immuno-oncology. Helped launch onto Nasdaq, navigate public markets, scale team, and execute strategy. Responsibilities: Financial Operations, Transactions, IR and Corp. Comms. * Led $115M IPO & Nasdaq listing (Morgan Stanley, Cowen, Jefferies). * Raised $84M private / crossover round. * Closed 2 Merck collaborations providing pembrolizumab for Ph 3 and Ph 2 trials. * Managed corporate re-organization into IO Biotech, Inc. Show less



Rezolute (BIO) Ireland Limited

• Board Member and Co-Founder

  • 2019 - 2021



Rezolute, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Financial Officer & Chief Strategy Officer

  • 2018 - 2021

  Company successfully taken public on Nasdaq (RZLT). Peak Mrk Cap while there >$200M. Raised >$100M. Clinical-stage biotech: orphan and metabolic. Helped launch onto Nasdaq, navigate public markets, scale team, and execute strategy. Responsibilities: Financial Operations, Transactions, IR and Corp. Comms. * Led $41M PIPE (Federated, BVF) & Nasdaq listing (CG, JMP, Griffin). * Raised $49M strategic financing (CG, JMP). * Led $50M ATM (Opco), $200M Shelf, and $30M venture… Show more Company successfully taken public on Nasdaq (RZLT). Peak Mrk Cap while there >$200M. Raised >$100M. Clinical-stage biotech: orphan and metabolic. Helped launch onto Nasdaq, navigate public markets, scale team, and execute strategy. Responsibilities: Financial Operations, Transactions, IR and Corp. Comms. * Led $41M PIPE (Federated, BVF) & Nasdaq listing (CG, JMP, Griffin). * Raised $49M strategic financing (CG, JMP). * Led $50M ATM (Opco), $200M Shelf, and $30M venture debt. * Drove partnership with Xoma. Show less



Coherus BioSciences

• United States
• Biotechnology Research
• 200 - 300 Employee

• Chief of Staff to CEO & VP of Investor Relations

  • 2015 - 2017

  Company successfully taken public on Nasdaq (CHRS). Peak Mrk Cap while there >$1B. Raised $300M. Commercial-stage biotech / medtech: biosimilars and oncology. Helped navigate public markets, scale team, and execute strategy. Responsibilities: Strategy, Transactions, Special Situations, IR, and Corp. Comms. * Led $100M private placement, sr. convert. notes (HCRP, KKR). * Drove $72M FPO (Barclays underwritten). * Raised $128M FPO (JPMorgan, Citi, Cowen, BMO).



Booz & Company.

• Business Consulting and Services
• 1 - 100 Employee

• Management Consultant, Healthcare Strategy

  • 2013 - 2014

  Worked with boards and senior executives on strategy, execution, and M&A across healthcare verticals. * Advised large cap pharma (top line >$15B) on strategic direction for flagship asset (>$10B in sales). * Advised public biotech / med tech on go / no-go decision for international JV. * Advised health plan on successful $1.2B acquisition of managed care co. * Advised hospital system with >$10B in revenue on productivity initiatives.



Family

• Sabbatical

  • 2012 - 2012

  Full-time husband and father. Recreational downhill skier.



Eiger BioPharmaceuticals

• Biotechnology
• 1 - 100 Employee

• Financial Officer of Founding Team, VP of Finance & Corporate Development

  • 2009 - 2011

  Company successfully taken public on Nasdaq (EIGR). Peak Mrk Cap >$400M. Commercial-stage biotech: orphan and infective. Helped launch company, scale team, and execute strategy. Responsibilities: Financial Operations and Transactions. * Company formation, Stanford spin-out, venture financings. * Acquired PC & clinical assets from Stanford, AstraZeneca, and Merck. * Established Silicon Valley HQ.



Diobex

• Head of Corporate Development

  • 2007 - 2009

  Clinical-stage biotech / medtech: metabolic.



Threshold Pharmaceuticals

• Head of Business Development

  • 2004 - 2007

  Company successfully taken public on Nasdaq (THLD) and later merged into Molecular Templates (MTEM). Peak Mrk Cap while there >$500M. Raised >$100M. Clinical-stage biotech: urology and oncology. Led WW partnering for late stage pipeline. Sourced and managed relationships across pharma and biotech. Executed M&A. Supported financings. Key spokesman at numerous conferences WW. * $37M IPO & Nasdaq listing (BofA, CIBC, Lazard, WB). * $65M FPO (Morgan Stanley, CIBC, Lazard). *… Show more Company successfully taken public on Nasdaq (THLD) and later merged into Molecular Templates (MTEM). Peak Mrk Cap while there >$500M. Raised >$100M. Clinical-stage biotech: urology and oncology. Led WW partnering for late stage pipeline. Sourced and managed relationships across pharma and biotech. Executed M&A. Supported financings. Key spokesman at numerous conferences WW. * $37M IPO & Nasdaq listing (BofA, CIBC, Lazard, WB). * $65M FPO (Morgan Stanley, CIBC, Lazard). * Development partnership in Asia. Show less



Bank of America

• United States
• Banking
• 700 & Above Employee

• Investment Banker, Healthcare

  • 2001 - 2003

  Advised on M&A and executed financings that raised ~$450M across healthcare verticals. * $115M IPO and Nasdaq listing for ViaCell, S-1 filed Jan. 2002. * $28M PIPE for Regeneration Technologies. * $115M senior notes offering for Bausch & Lomb. * $125M convertible senior debentures offering for Edwards Lifesciences. * $115M convertible senior debentures offering for Sierra Health Services. * $65M revolving credit facility for Sierra Health Services.



JPMorgan Chase & Co.

• United States
• Financial Services
• 700 & Above Employee

• Investment Banker, Healthcare

  • 2000 - 2000



Novartis

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Commercial

  • 1999 - 1999